Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
about
Complement in Lupus Nephritis: New PerspectivesAtypical hemolytic uremic syndrome: from diagnosis to treatmentDysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advancesComplement regulators in human disease: lessons from modern genetics.Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studiesFever, Jaundice, Abdominal Pain, Skin Lesions, and Dark Urine for 2 Days.Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.Pharmacologic therapy for acute pancreatitisProtective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.Complement-Mediated Regulation of Metabolism and Basic Cellular ProcessesPeptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential.Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab.Early initiation of eculizumab treatment in patients with atypical haemolytic uraemic syndrome improves long-term outcomes: a pooled analysis of clinical trials.Neisseria cinerea bacteremia in a patient receiving eculizumab: a case report.Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.Eculizumab: A Review in Generalized Myasthenia Gravis.
P2860
Q26740491-2C77B06F-0F9D-402F-BD55-6D540E7810F0Q27023137-DA9EE049-E811-42E7-9519-01E85DD77CB4Q28070056-DD5CF138-E2A6-422F-9F01-BAAF3D895921Q33419261-E0B76E18-20C6-4902-A716-942D69CD388AQ33420172-F8A17CD7-8E61-4004-A40B-9444042EC5B4Q33423489-5E55031F-6EE0-4D46-B453-60BC712FD540Q33426602-B200D77F-7FEC-4BD2-AC8D-B5384680B31EQ33430882-F15AC7FA-E521-4BB3-8FE9-736EBBD7D553Q33783126-45CFEC3B-3843-4830-A18B-E883B4B74CA6Q34647420-6C72BE0F-DE19-4D30-9073-C0A15916B20CQ35221158-9808B110-E8D1-4CD2-A44D-51E0FF5A1072Q37248499-E949A66A-990A-48B7-8A89-1C50582DE30CQ38247280-39D717B6-A2DA-4E2B-96F3-7D039FC75028Q40593336-DA67E6EF-F654-492D-A074-05374C1C1D1FQ46077713-EAB8652F-5923-41D0-A031-07A556D1D0C8Q46270363-AC5CD6D8-6688-420C-B78C-4ECCAD2C403AQ48255838-2CF5B7ED-FEAA-4E40-B7C2-5E0D89EF8D6FQ50050547-019F4F30-975D-44F3-A6CB-50E19CA6AC0C
P2860
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@ast
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@en
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@nl
type
label
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@ast
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@en
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@nl
prefLabel
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@ast
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@en
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@nl
P2860
P3181
P1433
P1476
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
@en
P2860
P2888
P304
P3181
P356
10.1007/S40265-013-0147-7
P407
P577
2013-12-01T00:00:00Z
P6179
1017441415